284 related articles for article (PubMed ID: 21547910)
41. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.
Bakkar AA; Allory Y; Iwatsubo Y; de Medina SG; Maille P; Khreich N; Riou A; Leroy K; Vordos D; Abbou CC; Andujar P; Billebaud T; Chammings S; Conso F; De La Taille A; Fontaine E; Gattegno B; Ravery V; Sibony M; Radvanyi F; Chopin DK; Pairon JC
Mol Carcinog; 2010 Jan; 49(1):25-31. PubMed ID: 19722178
[TBL] [Abstract][Full Text] [Related]
42. Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.
di Martino E; Kelly G; Roulson JA; Knowles MA
Mol Cancer Res; 2015 Jan; 13(1):138-48. PubMed ID: 25223521
[TBL] [Abstract][Full Text] [Related]
43. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
44. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
[TBL] [Abstract][Full Text] [Related]
45. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
[TBL] [Abstract][Full Text] [Related]
46. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
[TBL] [Abstract][Full Text] [Related]
47. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
[TBL] [Abstract][Full Text] [Related]
48. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
49. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
50. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.
Lott S; Wang M; Zhang S; MacLennan GT; Lopez-Beltran A; Montironi R; Sung MT; Tan PH; Cheng L
Mod Pathol; 2009 May; 22(5):627-32. PubMed ID: 19287463
[TBL] [Abstract][Full Text] [Related]
51. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
52. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
53. Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
Blinova E; Samishina E; Deryabina O; Blinov D; Roshchin D; Shich E; Tumutolova O; Fedoseykin I; Epishkina A; Barakat H; Kaprin A; Zhandarov K; Perepechin D; Merinov D; Brykin G; Arutiunian K; Serebrianyi S; Mirontsev A; Kozdoba A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576020
[TBL] [Abstract][Full Text] [Related]
54. Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer.
Pandith AA; Hussain A; Khan MS; Shah ZA; Wani MS; Siddiqi MA
Asian Pac J Cancer Prev; 2016; 17(6):2787-93. PubMed ID: 27356691
[TBL] [Abstract][Full Text] [Related]
55. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
[TBL] [Abstract][Full Text] [Related]
56. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
57. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
58. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
59. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
[TBL] [Abstract][Full Text] [Related]
60. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
